Deals review
- Deals review
- Deal details
Immune Response initiates phase I trial of brain tumour vaccine
In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.
Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Related deals
ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
Immune Response licenses Hybridon's 2nd-generation CpG DNA adjuvant
Nexell Therapeutics initiates program to develop tumour cell test
Immune Response receives two U.S. patents
Aventis and Medigene sign strategic alliance for tumour vaccine
Immune Response to pursue development of preventive HIV vaccine
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer´s disease
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer´s disease
Related categories
- Therapeutic target
- Immune related disorders
- Oncology
- Industry sector
- Pharmaceutical
More deals
Latest deals
- Biovator and BASF sign technology development agreement
- Agfa HealthCare signs four-year agreement with Chinese partners for distribution of radiography solutions, potentially worth 500 million US dollar
- Omnicare Announces Acquisition of Continuing Care Rx
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- GreenVax Selects Xcellerex XDR Single-Use Bioreactors for New Vaccine and Biotherapeutics Program
Most viewed deals
- Recommended acquisition of Acambis plc ("Acambis") by Sanofi Pasteur Holding ("Sanofi Pasteur") by way of scheme of arrangement Posting of Scheme Document
- Bayer CropScience and Janssen PMP conclude research agreement:
- Omnicare Announces Acquisition of Continuing Care Rx
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us